The new glioblastoma result is not a better drug. It is a switchable platform.

Cancer surgery has long been forced into a hard tradeoff: cut wide enough to catch the spread and accept damaged healthy tissue, or cut conservatively and leave cells behind. A new category of switchable single-material platform is being built to break that choice, and the clearest example so far sits in Bingyang Shi's UTS mouse glioblastoma study with Harvard and Henan collaborators.

Glioblastoma is the test case. Five-year survival hovers near seven percent, and the blood-brain barrier blocks most drugs and radiation from reaching the cells that escape the visible margin. Shi's group built a single-atom 2D sheet carrying a fluorescent dye in the NIR-II window, which lights up tumor clusters as small as forty-four micrometers during the operation. The same near-infrared beam that excites the dye also heats the sheet afterwards, so any cancer left at the margin is killed by a second pass with the same light. In mice, the treatment prevented recurrence and produced full survival at sixty days.

The story is not a new drug. It is a platform pattern: one material, one wavelength, two jobs in sequence, switched by the surgeon rather than mixed in the body. Until human trials show the same switch holds in people, the mechanism is the news.